2026-01-12 - Analysis Report
**Report for Merck & Co Inc (MRK)**

### Company Overview
Pharmaceutical and biotech company. 

### Return Rate Comparison

* **Cumulative Return (MRK)**: 27.63%
* **Cumulative Return (VOO)**: 94.03%
* **Divergence**: -66.40 (-66.40% difference in cumulative return)

### Alpha, Beta Analysis
| Year | CAGR | MDD | Alpha | Beta | Cap(B) |
|------|------|-----|-------|-------|--------|
| 2016-2018  | 24.0% | 14.7% | 21.0% | 0.7 | 182.1B |
| 2017-2019  | 37.0% | 14.7% | 20.0% | 0.7 | 216.8B |
| 2018-2020  | 13.0% | 19.3% | -8.0% | 0.7 | 195.0B |
| 2019-2021  | 0.0% | 19.3% | -43.0% | 0.6 | 191.4B |
| 2020-2022  | 14.0% | 16.3% | 16.0% | 0.5 | 277.1B |
| 2021-2023  | 31.0% | 14.3% | 30.0% | 0.3 | 272.3B |
| 2022-2024  | -5.0% | 24.9% | -24.0% | 0.3 | 248.5B |
| 2023-2025  | -24.0% | 39.0% | -86.0% | 0.3 | 262.9B |

### Recent Stock Price Fluctuations

* **5-day SMA:** $109.29
* **20-day SMA:** $104.63
* **60-day SMA:** $96.42
* **Close:** $110.53
* **Last-market Movement:** -0.41 (sharp decline)

### RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence

* **MRI (Market Risk Indicator):** 0.70 (Medium Investment Recommended)
* **RSI (Relative Strength Index):** 84.31
* **PPO (Percentage Price Oscillator):** 0.23
* **Hybrid Signal:** Buy (Risk Level: Medium)
* **Recent Relative Divergence Change:** 1.40 (improving)
* **7-day Rank Change:** -3 (rank down)
* **7-day Dynamic Expected Return Change:** 0.60 (improving)
* **Expected Return:** -26.70% (Expected excess return compared to S&P 500 if invested long-term)

### Recent News & Significant Events
* 
```text
[2025-12-24] Is Merck Stock’s Run Legitimate? - Forbes
[2026-01-09] What Is Happening With Merck Stock? - Trefis
[2025-12-16] Merck (MRK) Price Target Lifted at Morgan Stanley as Biopharma Outlook Improves - Yahoo Finance
[2026-01-11] New York State Teachers Retirement System Lowers Stock Position in Merck & Co., Inc. $MRK - MarketBeat
[2026-01-09] Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play - TechStock²
[2026-01-08] Merck: Fundamentals Amplified By A Momentum Breakout (NYSE:MRK) - Seeking Alpha
```

### Analyst Opinions
```text
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 113.33 / 135.00 / 83.00
```

### Recent Earnings Analysis
| Date | EPS | Revenue |
|------|-----|---------|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-02-05 | 1.25 | 16.66 B$ |

### Financial Information
#### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

#### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

### Comprehensive Analysis
Merck & Co Inc's stock has had a decline in recent times, with the cumulative return being significantly lower than the S&P 500. The company's earnings growth and profitability have been stable, however the relative divergence of 25.20% indicates a possible fluctuation. The stock's price fluctuations have been a concern, with a sharp decline. The recent news and significant events show a positive trend, with an increase in stock price and biopharma outlook improvements. The analysts' consensus recommends a buy, with a target price of $113.33. However, the company's expected return of -26.70% indicates a potential risk. Overall, the report suggests caution when investing in Merck & Co Inc's stock.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.